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We synthesized new 1-[3-(2-oxobenzothiazolin-3-yl)propanoyl]-4-substituted-thiosemicarbazides and
their corresponding cyclized 3-[2-(2-oxobenzothiazoline-3-yl)ethyl]-4-substituted-1,2,4-triazol-5-thione analogs in which position 4 of the triazole ring was substituted by cyclohexyl, methyl, allyl, phenyl, pmethylphenyl, p-methoxyphenyl, p-chlorophenyl, p-nitrophenyl, benzyl, and phenylethyl to screen their
analgesic and anti-inﬂammatory activities as well as gastric ulceration potential in test animals. None
of the compounds, except 5a, 5e, and 5h, caused gastric lesions or bleeding. Compound 5g was found
to have higher analgesic and anti-inﬂammatory activity among the synthesized compounds.
Key Words: 2-Benzothiazolinone, thiosemicarbazide, 1,2,4-triazol-5-thione, analgesic and anti-inﬂammatory
activity.

Introduction
Prostaglandins (PGs), which are produced via degradation of arachidonic acid by cyclooxygenase enzymes
(COXs), have various biological eﬀects in the human body. Their main functions are to control a variety
of physiological processes and to mediate pain and inﬂammatory responses. COX activity originates from 2
distinct and independently regulated enzymes, namely COX-1 and COX-2 isoforms. While COX-1 ensures
normal production of PGs, which have protecting roles in the gastrointestinal tract, the inducible form, COX2, was found almost exclusively in inﬂamed tissues as a canse of inﬂammatory stimuli. The inhibition of
COX-2 isoforms, which results in a decrease in the amount of inﬂammatory PGs, is the mechanism of action
of currently used non-steroidal anti-inﬂammatory drugs (NSAIDs). There are classical NSAIDs that inhibit
both COX-1 and COX-2, to varying extents. NSAIDs are among the most widely used therapeutics, primarily
for the treatment of pain and inﬂammation, including arthritis. The principal side eﬀect associated with
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chronic consumption of NSAIDs is signiﬁcant gastrointestinal irritation and the formation of life-threatening
gastrointestinal ulcers, which limits the therapeutic utilization of this type of drug. For this reason, selective
COX-2 inhibitors were developed in order to improve the gastrointestinal safety proﬁle of NSAIDs. However,
COX-2 inhibitors have recently been linked to an increased risk of adverse cardiovascular events.1−4 A recent
discovery, the third COX isoform (COX-3) enzyme, primary expressed in the brain and the heart, is thought
to be the target for acetaminophen.5,6 Therefore, the development of new compounds with analgesic and
anti-inﬂammatory activities that do not produce the previously mentioned side eﬀects still constitutes a
challenge for researchers.
1,2,4-Triazol-5-thione derivatives with antibacterial,7−9 antidepressant,10 antiviral,11 diuretic,12 and
hypoglycemic13 activities have been previously reported. Meanwhile, many reports suggest that acylthiosemicarbazides and their 1,2,4-triazole analogs may exhibit anti-inﬂammatory activity.
1-(1-Naphthyloxy)acetyl-4-substituted-3-thiosemicarbazides, 3-(1-naphthyloxy)methyl-4-substituted1,2,4-triazol-3-thiones, 1-(2-naphthyloxy)acetyl-4-substituted-3-thiosemicarbazides, and 5-(2-naphthyloxy)
methyl-4-substituted-1,2,4-triazol-3-thiones reported by Palaska and co-workers showed signiﬁcant analgesic
and anti-inﬂammatory activity.14,15 (Figure 1)
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Figure 1. 3-(1-Naphthyloxy)methyl-4-substituted-1,2,4-triazol-3-thiones and 5-(2-naphthyloxy)methyl-4-substituted1,2,4-triazol-3-thiones derivatives.

In addition, 5-alkoxyphenyl-3-carboxyalkylthio-1,2,4-triazol, 4-(aryl-2/9-substituted indophenazine-6acetyl)-3-thiosemicarbazide, and their corresponding cyclized 1,2,4-triazol-5-thione derivatives, 3-(1-adamantoyl)-4-substituted-1,2,4-triazol-5-thione, and 5-(3,5-ditert-butyl-4-hydroxyphenyl)-1,2,4-triazol-3-thione derivatives have been shown to exhibit anti-inﬂammatory and analgesic activity.16−19
A large number of 2-oxobenzothiazoline derivatives bearing various substituents at position 3 have
been reported to exhibit analgesic and anti-inﬂammatory activity.

Doğruer et al.

synthesized 3-(2-

benzothiazolinon-3-yl)acetamide derivatives, indicating that these compounds showed potential analgesic
and anti-inﬂammatory activity.20,21 In our previous work, we also prepared and reported the analgesic activity of 3-(2-oxobenzothiazolin-3-yl)propanamide derivatives and 3-(3-aminopropyl)-2-oxobenzothiazoline
hydrochloride derivatives. Some of these compounds have been found to have noteworthy antinociceptive
activity.22
In a previous study, we reported the synthesis of [(2-oxobenzothiazolin-3-yl)methyl]-4-alkyl/aryl1,2,4-triazolin-5-thiones and their antinociceptive activity. All of the compounds showed potent analgesic
activity in the AcOH induced stretching test. In particular, phenyl and phenylethyl derivatives exhibited
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antinociceptive activity 2-fold greater than that of aspirin. Methyl and p-nitrophenyl derivatives were found
to be more active than aspirin in the same test.23 (Figure 2)

S
R: Methyl, ethyl, allyl, phenyl, p-chlorophenyl,
p-methylphenyl, p-nitrophenyl, p-methoxyphenyl,
benzyl, phenylethyl.
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Figure 2. [(2-Oxobenzothiazolin-3-yl)methyl]-4-alkyl/aryl-1,2,4-triazolin-5-thiones derivatives.

These ﬁndings have prompted us to prepare the 1-[3-(2-oxobenzothiazolin-3-yl)propanoyl]-4-substitutedthiosemicarbazides and their corresponding cyclized 3-[2-(2-oxobenzothiazoline-3-yl)ethyl]-4-substituted-1,2,4triazol-5-thione analogs to explore their analgesic and anti-inﬂammatory activity.

Experimental
Chemistry
All chemicals and solvents were purchased locally from Merck AG and Aldrich Chemicals. Melting points
were determined with an Electrothermal-9200 Digital Melting Point Apparatus and are uncorrected. IR
spectra of the compounds were recorded on a Bruker Vector 22 FT-IR spectrophotometer (Opus Spectroscopic Software Version 2.0).

1

H-NMR spectra were recorded in DMSO-d6 on a Bruker Avance DPX-400

NMR spectrometer using tetramethylsilane as the internal standard. All chemical shifts were recorded as
δ (ppm). Microanalyses for C, H, and N were performed on a Leco-932 at TÜBİTAK (The Scientiﬁc and
Technological Research Council of Turkey) Analytical Laboratory, Ankara, Turkey, and they were within
the range of ± 0.4% of the theoretical value. The synthesis of 2-oxobenzothiazoline24 (1) and methyl
3-(2-oxobenzothiazolin-3-yl)propanoate25 (2) was previously reported.

3-(2-Oxobenzothiazoline-3-yl)propanohydrazide (3)
In 30 mL of ethanol were dissolved 0.01 mol methyl 3-(2-oxobenzothiazolin-3-yl)propanoate (2) and 0.2 mol
50% hydrazine hydrate. The ﬁnal mixture was stirred for 30 min at room temperature. The precipitate
formed was ﬁltered and washed with water. The solid material was dried and recrystallized from methanol
to yield 84%. mp: 171-172 ◦ C. FT-IR (KBr), cm−1 : 3322.4 (N-H), 1668.0, 1630.3 (C=O), 1 H-NMR (DMSOd6 )δ: 9.12 (1H, s, -NH-), 7.65 (1H, dd, benzothiazolone H7 ), 7.42-7.34 (2H, m, benzothiazolone H4 , H5 ),
7.24-7.16 (1H, m, benzothiazolone H6 ), 4.17 (2H, d, -NH2 ), 4.13 (2H, t, -N-CH2 -CH2 -), 2.43 (2H, t, -CH2 CH2 -CO-). Formula C10 H11 N3 O2 S.
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Synthesis of 1-[3-(2-Oxobenzothiazolin-3-yl)propanoyl]-4-substituted thiosemicarbazide derivatives (4a-4j)
We reﬂuxed 0.01 mol 3-(2-oxobenzothiazolin-3-yl)propanohydrazide (3) and 0.01 mol appropriate substituted isothiocyanate derivatives in methanol for a given period. At the end of this period, the reaction
mixture was cooled and the precipitate that formed was ﬁltered, washed with methanol, and then the solid
material was dried and recrystallized from appropriate solvents.

1-[3-(2-Oxobenzothiazolin-3-yl)propanoyl]-4-cyclohexylthiosemicarbazide 4a
Recrystallized from ethanol to yield 81.7%. mp: 211◦C. Reaction time is 3 h. FT-IR (KBr), cm−1 : 3312.4,
3293.8, 3136.3 (N-H), 1690.4, 1657.2 (C=O), 1 H-NMR (DMSO-d6 )δ: 9.68 (1H, s, -CO-NH-NH-CS-), 8.92
(1H, s, -CO-NH-NH-CS-), 7.58 (1H, dd, benzothiazolone H7 ), 7.33-7.11 (4H, m, benzothiazolone H4 , H5 ,
H6 , -CS-NH-C6 H11 ), 4.10 (2H, t, -N-CH2 -CH2 -), 2.50 (2H, t, -CH2 -CH2 -CO-), 1.70- 1.48 (5H, m, cyclohexyl
eqv.), 1.24-0.98 (6H, m, cyclohexyl axial). Formula C17 H22 N4 O2 S2 .

1-[3-(2-Oxobenzothiazolin-3-yl)propanoyl]-4-methyl thiosemicarbazide 4b
Recrystallized from ethanol to yield 76.4%. mp: 195 ◦ C. Reaction time is 5 h. FT-IR (KBr), cm−1 : 3295.1,
3123.8 (N-H), 1684.0, 1668.8 (C=O), 1 H-NMR (DMSO-d6 )δ: 9.84 (1H, s, -CO-NH-NH-CS-), 9.19 (1H, s,
-CO-NH-NH-CS-), 7.84 (1H, d, -CS-NH-CH3 , J: 3.97 Hz), 7.67 (1H, dd, benzothiazolone H7 ), 7.43-7.37 (2H,
m, benzothiazolone H4 , H5 ), 7.24-7.20 (1H, m, benzothiazolone H6 ), 4.18 (2H, t, -N-CH2 -CH2 -), 2.87 (3H,
d, -CS-NH-CH3 , J: 4.25 Hz), 2.56 (2H, t, -CH2 -CH2 -CO-). Formula C12 H14 N4 O2 S2 .

1-[3-(2-Oxobenzothiazolin-3-yl)propanoyl]-4-allylthiosemicarbazide 4c
Recrystallized from methanol to yield 79.4%. mp: 175 ◦ C. Reaction time is 12 h. FT-IR (KBr), cm−1 3297.3
(N-H), 1683.3, 1662.0 (C=O), 1 H-NMR (DMSO-d6 )δ: 9.88 (1H, s, -CO-NH-NH-CS-), 9.25 (1H, s, -CO-NHNH-CS-), 8.04 (1H, t, -CS-NH-CH2 -CH=, J: 5.45 Hz), 7.67 (1H, dd, benzothiazolone H7 ), 7.43-7.36 (2H,
m, benzothiazolone H4 , H5 ), 7.24-7.20 (1H, m, benzothiazolone H6 ), 5.85-5.76 (1H, m, -NH-CH2 -CH=CH2 ),
5.14-5.09 (1H, dd, -NH-CH2 -CH=CH2 , HAX(trans) J: 17.25 Hz, HAB(gem) J: 1.72 Hz), 5.06-5.03 (1H, dd,
-NH-CH2 -CH=CH2 , HBX(cis) J: 10.32 Hz, HAB(gem) J: 1.72 Hz), 4.18 (2H, t, -N-CH2 -CH2 -), 4.10 (2H, t,
-NH-CH2 -CH=CH2 , J: 5.29 Hz), 2.57 (2H, t, -CH2 -CH2 -CO-). Formula C14 H16 N4 O2 S2 .

1-[3-(2-Oxobenzothiazolin-3-yl)propanoyl]-4-phenylthiosemicarbazide 4d
Recrystallized from ethanol to yield 75.0%. mp: 175-176 ◦ C. Reaction time is 6 h. FT-IR (KBr), cm−1 :
3229.5, 3179.4, 3076.0 (N-H), 1664.2 (C=O), 1 H-NMR (DMSO-d6 )δ: 10.08 (1H, s, -CS-NH-C6 H5 ), 9.58 (2H,
s, -CO-NH-NH-CS-), 7.67 (1H, dd, benzothiazolone H7 ), 7.40-7.32 (6H, m, benzothiazolone H4 , H5 , phenyl
H2 , H3 , H5 , H6 ), 7.23-7.18 (2H, m, benzothiazolone H6 , phenyl H4 ), 4.21 (2H, t, -N-CH2 -CH2 -), 2.63 (2H,
t, -CH2 -CH2 -CO-). Formula C17 H16 N4 O2 S2 .
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1-[3-(2-Oxobenzothiazolin-3-yl)propanoyl]-4-(4-methylphenyl)thiosemicarbazide 4e
Recrystallized from ethanol to yield 68.7%. mp: 176 ◦ C. Reaction time is 15 h. FT-IR (KBr), cm−1 : 3270.7,
3175.1 (N-H), 1688.7, 1656.5 (C=O), 1 H-NMR (DMSO-d6 )δ: 10.05 (1H, s, -CS-NH-C6 H4 -CH3 (p)), 9.51 (2H,
s, -CO-NH-NH-CS-), 7.67 (1H, dd, benzothiazolone H7 ), 7.39 (2H, d, benzothiazolone H4 , H5 ), 7.27-7.19
(3H, m, benzothiazolone H6 , phenyl H2 , H6 ), 7.14 (2H, d, phenyl H3 , H5 ), 4.21 (2H, t, -N-CH2 -CH2 -), 2.62
(2H, t, -CH2 -CH2 -CO-), 2.29 (3H, s, -C6 H4 -CH3 (p)). Formula C18 H18 N4 O2 S2 .
1-[3-(2-Oxobenzothiazolin-3-yl)propanoyl]-4-(4-methoxyphenyl)thiosemicarbazide 4f
Recrystallized from ethanol/water to yield 72.0%. mp: 130 ◦ C. Reaction time is 5 h. FT-IR (KBr), cm−1 :
3567.5, 3463.8, 3168.1 (N-H), 1684.9 (C=O), 1 H-NMR (DMSO-d6 )δ: 10.19 (1H, s, -CS-NH-C6 H4 -OCH3 (p)),
9.60 (2H, d, -CO-NH-NH-CS-), 7.81 (1H, dd, benzothiazolone H7 ), 7.56 (2H, d, benzothiazolone H4 , H5 ),
7.41-7.35 (3H, m, benzothiazolone H6 , phenyl H2 , H6 ), 7.08-7.04 (2H, m, phenyl H3 , H5 ), 4.37 (2H, t,
-N-CH2 -CH2 -), 3.91 (3H, s, -C6 H4 -OCH3 (p)), 2.77 (2H, t, -CH2 -CH2 -CO-). Formula C18 H18 N4 O3 S2 .
1-[3-(2-Oxobenzothiazolin-3-yl)propanoyl]-4-(4-chlorophenyl)thiosemicarbazide 4g
Recrystallized from ethanol to yield 80.2%. mp: 193 ◦ C. Reaction time is 10 min. FT-IR (KBr), cm−1 :
3265.7 (N-H), 1664.7 (C=O), 1 H-NMR (DMSO-d6 )δ: 10.09 (1H, s, -CS-NH-C6 H4 -Cl(p)), 10.00-9.42 (2H, m,
-CO-NH-NH-CS-), 7.67 (1H, dd, benzothiazolone H7 ), 7.49-7.38 (6H, m, benzothiazolone H4 , H5 , phenyl H2 ,
H3 , H5 , H6 ), 7.25-7.19 (1H, m, benzothiazolone H6 ), 4.21 (2H, t, -N-CH2 -CH2 -), 2.63 (2H, t, -CH2 -CH2 -CO-).
Formula C17 H15 ClN4 O2 S2 .
1-[3-(2-Oxobenzothiazolin-3-yl)propanoyl]-4-(4-nitrophenyl)thiosemicarbazide 4h
Recrystallized from ethanol to yield 80.0%. mp: 196-197 ◦ C. Reaction time is 6 h. FT-IR (KBr), cm−1 :
3249.4 (N-H), 1656.4 (C=O), 1510.1, 1342.7 (NO2 ), 1 H-NMR (DMSO-d6 )δ: 10.44-9.85 (3H, m, -NH-), 8.228.20 (2H, dd, phenyl H3 , H5 ), 7.88-7.86 (2H, dd, phenyl H2 , H6 ), 7.66 (1H, dd, benzothiazolone H7 ), 7.41-7.36
(2H, m, benzothiazolone H4 , H5 ), 7.24-7.19 (1H, m, benzothiazolone H6 ), 4.22 (2H, t, -N-CH2 -CH2 -), 2.66
(2H, t, -CH2 -CH2 -CO-). Formula C17 H15 N5 O4 S2 .
1-[3-(2-Oxobenzothiazolin-3-yl)propanoyl]-4-benzylthiosemicarbazide 4i
Recrystallized from ethanol to yield 81.0%. mp: 193 ◦ C. Reaction time is 5 h. FT-IR (KBr), cm−1 : 3266.9,
3163.9, 3057.2 (N-H), 1701.1, 1651.6 (C=O), 1 H-NMR (DMSO-d6 )δ: 9.93 (1H, s, -CO-NH-NH-CS-), 9.34
(1H, s, -CO-NH-NH-CS-), 8.41 (1H, d, -CS-NH-CH2 ), 7.67 (1H, dd, benzothiazolone H7 ), 7.41-7.19 (8H,
m, benzothiazolone H4 , H5 , H6 , phenyl H2 , H3 , H4 , H5 , H6 ), 4.74 (2H, d, -N-CH2 -C6 H5 ), 4.18 (2H, t,
-N-CH2 -CH2 -), 2.57 (2H, t, -CH2 -CH2 -CO-). Formula C18 H18 N4 O2 S2 .
1-[3-(2-Oxobenzothiazolin-3-yl)propanoyl]-4-(2-phenylethyl)thiosemicarbazide 4j
Recrystallized from ethanol to yield 63.0%. mp: 167-168 ◦ C. Reaction time is 14 h. FT-IR (KBr), cm−1 :
3402.4, 3156.5 (N-H), 1696.0, 1682.7 (C=O), 1 H-NMR (DMSO-d6 )δ: 10.03 (1H, s, -CO-NH-NH-CS-), 9.38
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(1H, s, -CO-NH-NH-CS-), 8.12 (1H, s, -CS-NH-CH2 -), 7.83 (1H, dd, benzothiazolone H7 ), 7.57-7.33 (8H, m,
benzothiazolone H4 , H5 , H6 , phenyl H2 , H3 , H4 , H5 , H6 ), 4.35 (2H, t, -N-CH2 -CH2 -), 3.78 (2H, q, -N-CH2 CH2 -C6 H5 ), 2.96 (2H, t, -N-CH2 -CH2 -C6 H5 ), 2.73 (2H, t, -CH2 -CH2 -CO-). Formula C19 H20 N4 O2 S2 .
Synthesis of 3-[2-(2-Oxobenzothiazolin-3-yl)ethyl]-4-substituted-1,2,4-triazol-5-thione derivatives (5a-5j)
In 30 mL of methanol was dissolved 0.01 mol appropriate thiosemicarbazide derivative and 0.01 mol sodium
hydroxide was added and reﬂuxed for a certain period. At the end of this period, the reaction mixture
was cooled and acidiﬁed to pH 2 with 5% hydrochloric acid, and then the precipitated product was ﬁltered,
washed with water, dried, and recrystallized from appropriate solvent.
3-[2-(2-Oxobenzothiazolin-3-yl)ethyl]-4-cyclohexyl-1,2,4-triazol-5-thione 5a
Recrystallized from methanol to yield 80.1%. mp: 194-196 ◦ C. Reaction time is 6 h. FT-IR (KBr), cm−1 :
3222.7 (N-H), 1646.3 (C=O), 1 H-NMR (DMSO-d6 )δ: 13.52 (1H, s, -NH), 7.68 (1H, dd, benzothiazolone H7 ),
7.42-7.36 (2H, m, benzothiazolone H4 , H5 ), 7.24-7.20 (1H, m, benzothiazolone H6 ), 4.28 (2H, t, -N-CH2 CH2 -), 3.16 (2H, t, -CH2 -CH2 -C=), 1.80- 1.59 (5H, m, cyclohexyl eqv.), 1.35-1.11 (6H, m, cyclohexyl axial).
Formula C17 H20 N4 OS2 .
3-[2-(2-Oxobenzothiazolin-3-yl)ethyl]-4-methyl-1,2,4-triazol-5-thione 5b
Recrystallized from methanol/water to yield 80.1%. mp: 252-253 ◦ C. Reaction time is 2 h.
(KBr), cm

−1

FT-IR

1

: 3232.8 (N-H), 1652.6 (C=O), H-NMR (DMSO-d6 )δ: 13.48 (1H, s, -NH), 7.67 (1H, dd,

benzothiazolone H7 ), 7.39-7.38 (2H, m, benzothiazolone H4 , H5 ), 7.24-7.20 (1H, m, benzothiazolone H6 ),
4.29 (2H, t, -N-CH2 -CH2 -), 3.43 (3H, s, -N-CH3 ), 3.08 (2H, t, -CH2 -CH2 -C=). Formula C12 H12 N4 OS2 .
3-[2-(2-Oxobenzothiazolin-3-yl)ethyl]-4-allyl-1,2,4-triazol-5-thione 5c
Recrystallized from methanol/water to yield 70.0%. mp: 166 ◦ C. Reaction time is 3 h. FT-IR (KBr),
cm−1 : 3104.1 (N-H), 1668.7, 1653.8 (C=O), 1 H-NMR (DMSO-d6 )δ: 13.62 (1H, s, -NH), 7.67 (1H, dd,
benzothiazolone H7 ), 7.38-7.37 (2H, m, benzothiazolone H4 , H5 ), 7.23-7.19 (1H, m, benzothiazolone H6 ),
5.90-5.83 (1H, m, -N-CH2 -CH=CH2 ), 5.19-5.16 (1H, dd, -N-CH2 -CH=CH2 , HAX(cis) J: 10.39 Hz, HAB(gem)
J: 1.17 Hz), 5.05-5.01 (1H, dd, -N-CH2 -CH=CH2 , HBX(trans) J: 17.23 Hz, HAB(gem) J: 1.2 Hz), 4.65 (2H,
d, -N-CH2 -CH=CH2 ), 4.29 (2H, t, -N-CH2 -CH2 -), 3.01 (2H, t, -CH2 -CH2 -C=). Formula C14 H14 N4 OS2 .
3-[2-(2-Oxobenzothiazolin-3-yl)ethyl]-4-phenyl-1,2,4-triazol-5-thione 5d
Recrystallized from isopropanol to yield 86.1%. mp: 255-256 ◦ C. Reaction time is 5 h. FT-IR (KBr), cm−1 :
3090.3 (N-H), 1669.2 (C=O), 1 H-NMR (DMSO-d6 )δ: 13.75 (1H, s, -NH), 7.64 (1H, dd, benzothiazolone H7 ),
7.56-7.53 (3H, m, phenyl H3 , H4 , H5 ), 7.44-7.42 (2H, m, phenyl H2 , H6 ), 7.28 (1H, t, benzothiazolone H4 ),
7.19 (1H, t, benzothiazolone H5 ), 7.03 (1H, d, benzothiazolone H6 ), 4.06 (2H, t, -N-CH2 -CH2 -), 2.82 (2H, t,
-CH2 -CH2 -C=). Formula C17 H14 N4 OS2 .
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3-[2-(2-Oxobenzothiazolin-3-yl)ethyl]-4-(4-methylphenyl)-1,2,4-triazol-5-thione 5e
Recrystallized from methanol/water to yield 82.5%. mp: 236-237 ◦ C. Reaction time is 3 h. FT-IR (KBr),
cm−1 : 3344.5 (N-H), 1676.0 (C=O), 1 H-NMR (DMSO-d6 )δ: 13.71 (1H, s, -NH), 7.64 (1H, dd, benzothiazolone H7 ), 7.35-7.27 (5H, m, phenyl H2 , H3 , H5 , H6 , benzothiazolone H4 ), 7.19 (1H, m, benzothiazolone
H5 ), 7.03 (1H, d, benzothiazolone H6 ), 4.05 (2H, t, -N-CH2 -CH2 -), 2.81 (2H, t, -CH2 -CH2 -C=), 2.38 (3H, s,
-C6 H4 -CH3 (p)). Formula C18 H16 N4 OS2 .
3-[2-(2-Oxobenzothiazolin-3-yl)ethyl]-4-(4-methoxyphenyl)-1,2,4-triazol-5-thione 5f
Recrystallized from methanol/water to yield 70.1%. mp: 230-231 ◦ C. Reaction time is 3 h.
(KBr), cm

−1

FT-IR

1

: 3095.5 (N-H), 1671.2 (C=O), H-NMR (DMSO-d6 )δ: 13.86 (1H, s, -NH), 7.80 (1H, dd,

benzothiazolone H7 ), 7.51-7.43 (3H, m, benzothiazolone H4 , phenyl H2 , H6 ), 7.35 (1H, t, benzothiazolone
H5 ), 7.24-7.20 (3H, m, benzothiazolone H6 , phenyl H3 , H5 ), 4.22 (2H, t, -N-CH2 -CH2 -), 3.98 (3H, s, -NC6 H4 -OCH3 (p)), 2.97 (2H, t, -CH2 -CH2 -C=). Formula C18 H16 N4 O2 S2 .
3-[2-(2-Oxobenzothiazolin-3-yl)ethyl]-4-(4-chlorophenyl)-1,2,4-triazol-5-thione 5g
Recrystallized from methanol to yield 84.0%. mp: 209-210 ◦ C. Reaction time is 2 h. FT-IR (KBr), cm−1 :
3187.6 (N-H), 1634.4 (C=O), 1 H-NMR (DMSO-d6 )δ: 13.77 (1H, s, -NH), 7.63-7.58 (3H, m, benzothiazolone
H7 , phenyl H3 , H5 ), 7.47-7.44 (2H, m, phenyl H2 , H6 ), 7.31-7.27 (1H, m, benzothiazolone H4 ), 7.19-7.15
(1H, m, benzothiazolone H5 ), 7.08 (1H, d, benzothiazolone H6 ), 4.05 (2H, t, -N-CH2 -CH2 -), 2.82 (2H, t,
-CH2 -CH2 -C=). Formula C17 H13 ClN4 OS2 .
3-[2-(2-Oxobenzothiazolin-3-yl)ethyl]-4-(4-nitrophenyl)-1,2,4-triazol-5-thione 5h
Recrystallized from methanol to yield 65.0%. mp: 263-264 ◦ C. Reaction time is 10 h. FT-IR (KBr), cm−1 :
3105.5 (N-H), 1631.8 (C=O), 1522.1, 1344.7 (NO2 ), 1 H-NMR (DMSO-d6 )δ: 13.77 (1H, s, -NH), 8.26-8.23
(2H, dd, phenyl H3 , H5 ), 7.67-7.64 (2H, dd, phenyl H2 , H6 ), 7.51 (1H, dd, benzothiazolone H7 ), 7.19-7.17
(1H, m, benzothiazolone H4 ), 7.08-7.06 (2H, m, benzothiazolone H5 , H6 ), 3.99 (2H, t, -N-CH2 -CH2 -), 2.82
(2H, t, -CH2 -CH2 -C=). Formula C17 H13 N5 O3 S2 .
3-[2-(2-Oxobenzothiazolin-3-yl)ethyl]-4-benzyl-1,2,4-triazol-5-thione 5i
Recrystallized from methanol/water to yield 93.6%. mp: 220-221 ◦ C. Reaction time is 3 h.
(KBr), cm

−1

FT-IR

1

: 3193.0 (N-H), 1643.8 (C=O), H-NMR (DMSO-d6 )δ: 13.89 (1H, s, -NH), 7.80 (1H, dd,

benzothiazolone H7 ), 7.53-7.28 (8H, m, benzothiazolone H4 , H5 , H6 , phenyl H2 , H3 , H4 , H5 , H6 ), 5.45 (2H,
s, -N-CH2 -C6 H5 ), 4.30 (2H, t, -N-CH2 -CH2 -), 3.07 (2H, t, -CH2 -CH2 -C=). Formula C18 H16 N4 OS2 .
3-[2-(2-Oxobenzothiazolin-3-yl)ethyl]-4-(2-phenylethyl)-1,2,4-triazol-5-thione 5j
Recrystallized from butanol to yield 74.2%. mp: 85-87 ◦ C. Reaction time is 4 h. FT-IR (KBr), cm−1 : 3390.7
(N-H), 1674.2 (C=O), 1 H-NMR (DMSO-d6 )δ: 13.60 (1H, s, -NH), 7.66 (1H, dd, benzothiazolone H7 ), 7.38
(1H, m, benzothiazolone H4 ), 7.29-7.20 (5H, m, benzothiazolone H5 , phenyl H2 , H3 , H5 , H6 ), 7.16-7.14 (2H,
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m, benzothiazolone H6 , phenyl H4 ), 4.18 (2H, t, -N-CH2 -CH2 -), 4.11 (2H, t, -N-CH2 -CH2 -C6 H5 ), 2.99 (2H,
t, -N-CH2 -CH2 -C6 H5 ), 2.70 (2H, t, -CH2 -CH2 -C=). Formula C19 H18 N4 OS2 .

Pharmacology
Animals
Male Swiss albino mice (The Animal Breeding Laboratories of Reﬁk Saydam Hıfz-ı Sıhha Institute, Ankara,
Turkey), weighing 20-25 g, were used for all experiments. The animals were kept in colony cages (6 mice
each), maintained on a standard pellet diet with water ad libitum, and left for 2 days for acclimatization
before the experimental session. The food was withdrawn on the day before the experiment, but free access
to water was allowed. All experiments were carried out according to the suggested ethical guidelines for the
care of laboratory animals.

Preparation of test samples for bioassay
Test samples were suspended in a mixture of distilled water and 0.5% sodium carboxymethylcellulose (CMC)
and were given orally to the test animals. The animals of the control group received the same experimental
handling, except that the drug treatment was replaced with appropriate volumes of only the dosing vehicle.
Indomethacin (10 mg/kg) and acetylsalicylic acid (ASA) in 0.5% CMC (100 mg/kg) were used as reference
drugs.

p-Benzoquinone-induced writhing test26
The mice were injected intraperitoneally with 0.1 mL/10 g body weight of 2.5% (v/v) p-benzoquinone (PBQ,
Merck, Darmstadt, Germany) solution in distilled water 60 min after the oral administration of test samples.
Control animals received an appropriate volume of dosing vehicle. The mice were then kept individually for
observation and the total number of abdominal contractions (writhing movements) was counted for the next
15 min, starting 5 min after the PBQ injection. The data represent average values of the total number of
writhings observed. The analgesic activity was expressed as the percentage change from writhing controls.

Carrageenan-induced hind paw edema test27,28
The test was performed according to the method of Kasahara et al.28 The diﬀerence in footpad thickness
between the right and left foot was measured with a pair of dial thickness gauge calipers (Ozaki Co., Tokyo,
Japan). Mean values of treated groups were compared with mean values of a control group and analyzed
using statistical methods. Sixty minutes after the oral administration of the test sample or dosing vehicle,
each mouse was injected with a freshly prepared (0.5 mg/25 mL) suspension of carrageenan (Sigma, St.
Louis, MO, USA) in physiological saline (154 mM NaCl) into the subplantar tissue of the right hind paw
and 25 µL of saline solution was injected into that of the left hind paw as a secondary control. Measurements
were obtained and evaluated every 90 min for 360 min following the induction of inﬂammation, as described
above.
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Gastric ulceration side eﬀects
After the analgesic activity experiment, the mice were euthanized under deep ether anesthesia and their
stomachs were removed. Then, the abdomen of each mouse was opened through great curvature and
examined under a dissecting microscope for lesions or bleeding.

Statistical analysis of data

Data obtained from the animal experiments are expressed as the mean standard error (± SEM). Statistical
diﬀerences between the treatments and the control were tested by ANOVA test.

Results and Discussion
The synthetic pathway leading to the title compounds is given in Scheme. 2(3H)-Oxobenzothiazolin (1), the
starting material, was synthesized according to the previously published procedure, using 2-aminothiophenol
and urea.24 1 was reacted with methyl acrylate to obtain methyl [3-(2-oxobenzothiazolin-3-yl)]propanoate
(2),25 which was subsequently reacted with hydrazine hydrate to produce 3-(2-oxobenzothiazolin-3-yl)propanohydrazide (3). The reaction of the hydrazide derivative with isothiocyanate derivatives resulted in the formation of 1-[3-(2-oxobenzothiazolin-3-yl)propanoyl]-4-substituted thiosemicarbazides (4). Finally, cyclization of 4 in basic media produced the title compounds, 3-[2-(2-oxobenzothiazolin-3-yl)ethyl]-4-substituted1,2,4-triazol-5-thione derivatives (5). All the 3-(2-oxobenzothiazolin-3-yl)propanohydrazide (3), 1-[3-(2oxobenzothiazolin-3-yl)propanoyl]-4-substituted thiosemicarbazides (4), and 3-[2-(2-oxobenzothiazolin-3-yl)
ethyl]-4-substituted-1,2,4-triazol-5-thiones derivatives (5) synthesized in this study are reported for the ﬁrst
time.
The structures of the compounds have been elucidated by IR, 1 H-NMR, and microanalyses. Reaction
time, crystallization solvents, melting points, % yields, and spectral data of the compounds are given in the
Experimental Part.
The IR spectra of 1-[3-(2-oxobenzothiazolin-3-yl)propanoyl]-4-substituted thiosemicarbazides (4)
showed N-H stretching bands between 3057 and 3402 cm−1 , and 2 C=O stretching bands at 1651-1701
cm−1 . 1,2,4-Triazol-5-thione derivatives (5) showed N-H stretching bands at 3090-3390 cm−1 and C=O
stretching bands at 1631-1674 cm−1 . In the 1 H-NMR spectra, the N-H protons of compounds 4a-j were
observed at 9.42-10.44 (CO-NH), 8.92-10.44 (HN-CS), and 7.11-10.44 (HN-R) ppm. Also observed were
aromatic phenyl protons and 2-oxobenzothiazoline groups at 8.22-7.04 ppm, and ethylenic protons at 4.374.10 (-N-CH2 -CH2 -) and 2.77-2.50 (-CH2 -CH2 -CO) ppm. We observed N-H protons of compounds 5a-j at
13.48-13.89 ppm, aromatic protons of phenyl rings and 2-oxobenzothiazoline groups at 8.26-7.01 ppm, and
ethylenic protons at 4.30-3.99 (-N-CH2 -CH2 -) and 3.16-2.70 (-CH2 -CH2 -C=) ppm.
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SH

NH2
C

+

O

NH2

NH2

S

2NH 3

O

1

N

180 C

H

O
Triethylamine + CH CH C
2
60 C
S

S

NH2N H2

O

O

N

O

N

O

CH2CH2 C

N H N H2

CH2CH2 C

N

C

OCH3

2

3
+ S

OCH3

R

S

R
O

O

S

CH2CH2 C

NH NH C

N

NH

R

4a-4j

NaOH
S
O

N
CH2 CH2 C

N

N

N

R

C

a Cyclohexyl
b Methyl
c Allyl
d Phenyl
e p-Methylphenyl
f p-Methoxyphenyl
g p-Chlorophenyl
h p-Nitrophenyl
i Benzyl
j Phenylethyl

5a-5j

H

S
Scheme. Synthetic route of the title compounds.

In this preliminary screening study, analgesic and anti-inﬂammatory activity of the title compounds
(5a-5j) were assessed by the p-benzoquinone-induced writhing test26 and carrageenan-induced hind paw
edema model,27,28 respectively. As seen in Tables 1 and 2, the overall analgesic and anti-inﬂammatory
activity of the compounds were lower than those of the reference compounds, aspirin and indomethacin,
respectively. In the p-benzoquinone-induced writhing test, some of the compounds showed signiﬁcant activity
and the highest potency was exhibited by compound 5g. In addition, compounds 5a and 5h were inactive
in the same test system. Compound 5g exhibited the highest anti-inﬂammatory activity at 100 mg/kg,
although it was less pronounced than that of the reference compound, indomethacin, tested at the 10 mg/kg
dose. Compounds 5a, 5f, and 5h were inactive in the same test. Additionally, none of the compounds,
except for 5a, 5e, and 5h, caused any gastric lesions or bleeding in the stomachs of the tested animals.
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Table 1. Eﬀect of the synthesized compounds against p-benzoquinone-induced writhing in mice.a

Compounds
Control
5a
5b
5c
5d
5e
5f
5g
5h
5i
5j
ASA

Dose
(mg/kg)

Number of writhings ± SEM

Inhibitory
ratio (%)

100
100
100
100
100
100
100
100
100
100
100

42.7 ± 3.98
43.3± 3.10
33.1 ± 2.97
29.2 ± 3.02
36.5 ±2.19
30.5 ± 2.92
40.9 ± 2.45
23.8 ± 2.34
43.5 ± 3.96
31.9 ± 2.18
34.7 ± 3.08
21.3 ± 2.05

—22.5
31.6**
14.5
28.6**
4.2
44.3***
—25.3*
18.7
50.1***

Ratio of
ulceration
0/6
1/6
0/6
0/6
0/6
1/6
0/6
0/6
2/6
0/6
0/6
4/6

(* P < 0.05, ** P < 0.01, *** P <0.001).
a

Analgesic activity of the compounds and aspirin was tested at the 100 mg/kg dose, as described in the Experimental

Part. P < 0.5 was found for all tests in comparison to the control group.

Table 2. Eﬀects of the synthesized compounds against carrageenan-induced paw edema in mice.a

Compounds

Dose
(mg/kg)

Control
5a
5b

100
100

5c

100

5d

100

5e

100

5f
5g

100
100

5h
5i

100
100

5j

100

Indomethacin

10

Swelling thickness (×10−2
90 min
180 min
43.4 ± 4.36 49.1 ± 4.02
46.9 ± 4.02 54.2 ± 3.11
40.1 ± 2.18 43.2 ± 2.56
(7.6)
(12.0)
35.8 ± 3.12 38.9 ± 3.45
(17.5)
(20.8)
42.7 ± 3.11 48.9 ± 3.34
(1.6)
(1.8)
34.9 ± 2.58 40.1 ± 3.45
(19.6)
(18.3)
45.1 ± 2.91 52.6 ± 2.89
33.4 ± 3.03 36.8 ± 2.46
(23.0)
(25.1)*
44.7 ± 3.12 51.8 ± 2.98
39.2 ± 3.14 41.2 ± 3.67
(9.7)
(16.1)
41.4 ± 2.98 46.7 ± 3.01
(4.6)
(4.9)
31.3 ± 2.65 30.2 ± 2.11
(27.9)*
(38.5)**

mm) ± SEM (inhibition %)
270 min
360 min
53.9 ± 3.81 57.8 ± 4.12
58.9 ± 3.98 64.5 ± 4.13
47.9 ± 2.67 50.1 ± 2.88
(11.1)
(13.3)
41.3 ± 3.09 43.9 ± 2.98
(23.4)
(24.0)*
52.3 ± 4.12 55.8 ± 3.98
(2.9)
(3.5)
43.6 ± 2.98 45.8 ± 3.15
(19.1)
(20.8)
57.9 ± 2.11 61.3 ± 3.01
38.9 ± 2.37 40.3 ± 2.89
(27.8)**
(30.3)**
55.9 ± 3.01 60.1 ± 3.13
45.7 ± 3.12 48.7 ± 3.56
(15.2)
(15.7)
50.4 ± 3.92 53.1 ± 3.26
(6.5)
(8.1)
31.4 ± 2.10 33.8 ± 2.24
(41.7)***
(41.5)***

(* P < 0.05, ** P < 0.01, *** P < 0.001).
a

Anti-inﬂammatory activity of the compounds was tested at the 100 mg/kg dose, and anti-inﬂammatory activity of

the reference compound, indomethacin, was tested at the 10 mg/kg dose, as described in the Experimental Part. P
< 0.5 was found for all tests in comparison to the control group.
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In a previous study, [(2-oxobenzothiazolin-3-yl)methyl]-4-phenyl-1,2,4-triazoline-5-thiones and [(2oxobenzothiazolin-3-yl)methyl]-4-phenylethyl-1,2,4-triazoline-5-thiones exhibited antinociceptive activity 2fold greater than that of aspirin, and all of the compounds showed potent activity in the acetic acid-inducedstretching test.21
As a result, we may conclude that when the distance between the 1,2,4-triazoline-5-thione ring and the
2-oxobenzothiazoline was increased by 2 carbon atoms, the activity of these compounds decreased and the
carbon chain length between the 2-ring system was important for analgesic and anti-inﬂammatory activity.
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